Longer follow-up shows improved DFS with nivolumab in high-risk muscle-invasive urothelial carcinoma

Article

Treatment with nivolumab (Opdivo) continued to induce improved disease-free survival (DFS) among patients with high-risk muscle-invasive urothelial carcinoma (MIUC) following radical surgery, regardless of previous treatment with neoadjuvant chemotherapy, nodal involvement, or PD-L1 status, according to extended follow-up from the phase 3 Checkmate 274 trial (NCT02632409) presented at the 22nd Annual Meeting of the Society of Urologic Oncology.1

Matthew Galsky, MD

Matthew Galsky, MD

“With longer follow-up, nivolumab continued to demonstrate a clinically meaningful improvement in disease-free survival versus placebo for patients with high-risk muscle invasive urothelial cancer after radical surgery. This disease-free survival benefit was observed in both the intent to treat [ITT] population and in the subset of patients with tumors harboring high levels of PD-L1 expression, a disease-free survival benefit with nivolumab was observed in most pre-specified clinical subgroups,” Matthew Galsky, MD, professor of medicine (hematology and medical oncology); director of genitourinary medical oncology; co-director of the Center of Excellence for Bladder Cancer at The Tisch Cancer Institute; and associate director for translational research at The Tisch Cancer Institute at Mount Sinai, said during a virtual presentation of the poster.

The randomized, double-blind, multicenter phase 3 CheckMate 274 trial enrolled a total of 709 patients with high-risk MIUC, originating in the bladder, ureter, or renal pelvis, including 353 in the ITT nivolumab group (PD-L1 ≥1%, n = 140) and 356 in the placebo group (PD-L1 ≥1%, n = 142). Additionally, 140 patients in the nivolumab arm and 142 in the placebo arm had a PD-L1 expression of 1% or more.2

Patients were randomized 1:1 and stratified based on PD-L1 expression, pathological nodal status, and treatment with a neoadjuvant cisplatin-based chemotherapy. A dose of 240 mg of nivolumab or placebo was administered every 2 weeks intravenously for up to a year or until disease recurrence or trial discontinuation.

The primary end point of the study was DFS for all patients in the ITT population, as well as those with a PD-L1 expression of 1% or greater. The key secondary end point was NUTRFS in the ITT population and in patients with PD-L1 ≥1%. Moreover, DMFS was an exploratory end point. DFS was also evaluated in prespecified subgroups.

To be eligible for the trial, the high-risk population of patients with MIUC who had previously undergone radical surgery needed to have undergone radical surgery with or without cisplatin-based chemotherapy within 120 days prior to randomization, and were required to have an ECOG performance status of 0 or 1.

Following a previous minimum follow-up in the ITT population of 5.9 months, DFS was significantly improved with nivolumab, compared with placebo, both in the ITT population (HR, 0.70; 98.22% CI, 0.55-0.90; P <.001) and in the population with tumor PD-L1 expression ≥1% (HR, 0.55; 98.72% CI, 0.35-0.85; P < .001). The safety profile of nivolumab was consistent with that observed in previous trials.

Following an additional follow-up of 5 months, which included a minimum follow-up in the intention-to-treat (ITT) population of 11 months (median follow-up in the nivolumab vs placebo group, 24.4 months vs 22.5 months, respectively) and 11.4 months in the PD-L1 ≥1% group (median follow-up in the nivolumab vs placebo group, 25.5 months vs 22.4 month), DFS benefit with nivolumab was maintained.

With the longer follow-up, the anti-PD-1 antibody demonstrated improved DFS, compared with placebo, in the ITT nivolumab and placebo groups (22.0 months vs 10.9 months, respectively), as well as in the PD-L1 ≥1% groups (not reached [NR] vs 8.4 months). DFS probability at 12 months was 63.5% with nivolumab and 46.9% with placebo in ITT patients, and 67.6% vs 46.3%, respectively, among patients with PD-L1 ≥1%.

In the subgroup analysis, improved DFS was observed with nivolumab, compared with placebo, for those in subgroups including age (<65: HR, 0.73; 95% CI, 0.53-1.01), sex (female: HR, 0.77, 95% CI, 0.50-1.17), ECOG performance status (1: HR, 0.79; 95% CI, 0.56-1.12), nodal status (N0/x with <10 nodes removed: HR, 0.85; 95% CI, 0.57-1.27), use of prior cisplatin-based chemotherapy (No: HR, 0.90; 95% CI, 0.68-1.18), and PD-L1 status (<1%: HR, 0.82; 95% CI, 0.63-1.05).

At 12 months, non-urothelial tract recurrence-free survival (NUTRFS) probabilities were also improved with nivolumab, versus placebo, in both the ITT (65.8% vs 50.6%, respectively) and PD-L1 ≥1% (69.2% vs 47.1%) populations. The median NUTRFS in the ITT was 26.0 months [95% CI, 19.5-41.1] vs 13.7 months [95% CI, 8.4-20.0]; HR, 0.71; 95% CI, 0.58-0.88), respectively, and placebo (NR [95% CI, 25.8-not estimable (NE)] vs 10.8 months [95% CI, 5.7-20.7]; HR, 0.54; 95% CI, 0.39-0.77) groups was also improved with nivolumab.

Similarly, median distant metastasis-free survival (DMFS) was also improved with nivolumab, compared with placebo, in both the ITT (41.1 months [95% CI, 26.0-NE] vs 29.3 months [95% CI, 15.2-NE], respectively; HR, 0.73; 95% CI, 0.58-0.92) and PD-L1 ≥1% groups (NR [95% CI, 26.0-NE] vs 20.7 months [95% CI, 10.8-NE]; HR, 0.60; 95% CI, 0.41-0.88).

In terms of time to response, the median among the nivolumab and placebo groups, respectively, were 25.8 months (95% CI, 19.6-NE) and 11.1 months (95% CI, 8.3-19.4) in the ITT population, and NR (95% CI, 25.8-NE) and 10.9 months (95% CI, 5.8-22.2) in the PD-L1 ≥1% population.

Galsky added that subsequent systemic therapy was received by 30% of patients on the nivolumab arm and 37.6 patients on the placebo arm.

The median duration of therapy was 10.1 months (range, 0-12.5) in the nivolumab group, compared with 8.6 months (range, 0-12.6) in the placebo group.

“These results support adjuvant nivolumab as a standard of care for patients with high-risk muscle-invasive urothelial cancer after radical resection,” Galsky said.

Reference

1. Galsky MD, Witjes JA, Gschwend JE, et al. Disease-free survival with longer follow-up from the phase 3 Checkmate 274 trial of adjuvant nivolumab in patients who underwent surgery for high-risk muscle-invasive urothelial carcinoma. Presented at: SUO 22nd Annual Meeting; December 1-3, 2021; Orlando, Florida. Poster 175.

2. Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384(22):2102-2114. doi:10.1056/NEJMoa2034442.

Related Videos
Dr. Jasmeet Kaur in an interview with Urology Times
Dr. Martin Voss in an interview with Urology Times
Dr. Jacqueline Brown in an interview with Urology Times
blurred clinic hallway
Dr. Dalia Kaakour in an interview with red Urology Times backdrop
Dr. Maria Teresa Bourlon in an interview with Urology Times
Dr. David Braun in an interview with Urology Times
Dr. Neeraj Agarwal in an interview with Urology Times
Dr. Saby George in an interview with Urology Times
Dr. Laura Bukavina in an interview with Urology Times
Related Content
© 2024 MJH Life Sciences

All rights reserved.